Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, United States of America.
PLoS One. 2010 Jul 8;5(7):e11472. doi: 10.1371/journal.pone.0011472.
Leber's hereditary optic neuropathy (LHON) is a maternally inherited disorder with point mutations in mitochondrial DNA which result in loss of vision in young adults. The majority of mutations reported to date are within the genes encoding the subunits of the mitochondrial NADH-quinone oxidoreductase, complex I. Establishment of animal models of LHON should help elucidate mechanism of the disease and could be utilized for possible development of therapeutic strategies.
METHODOLOGY/PRINCIPAL FINDINGS: We established a rat model which involves injection of rotenone-loaded microspheres into the optic layer of the rat superior colliculus. The animals exhibited the most common features of LHON. Visual loss was observed within 2 weeks of rotenone administration with no apparent effect on retinal ganglion cells. Death of retinal ganglion cells occurred at a later stage. Using our rat model, we investigated the effect of the yeast alternative NADH dehydrogenase, Ndi1. We were able to achieve efficient expression of the Ndi1 protein in the mitochondria of all regions of retinal ganglion cells and axons by delivering the NDI1 gene into the optical layer of the superior colliculus. Remarkably, even after the vision of the rats was severely impaired, treatment of the animals with the NDI1 gene led to a complete restoration of the vision to the normal level. Control groups that received either empty vector or the GFP gene had no effects.
CONCLUSIONS/SIGNIFICANCE: The present study reports successful manifestation of LHON-like symptoms in rats and demonstrates the potential of the NDI1 gene therapy on mitochondrial optic neuropathies. Our results indicate a window of opportunity for the gene therapy to be applied successfully after the onset of the disease symptoms.
Leber 遗传性视神经病变(LHON)是一种母系遗传疾病,其线粒体 DNA 中的点突变导致年轻人视力丧失。迄今为止报告的大多数突变都在编码线粒体 NADH-醌氧化还原酶复合物 I 亚基的基因内。建立 LHON 的动物模型应该有助于阐明疾病的机制,并可用于开发可能的治疗策略。
方法/主要发现:我们建立了一种大鼠模型,该模型涉及将载有鱼藤酮的微球注入大鼠上丘的视神经层。这些动物表现出 LHON 最常见的特征。在鱼藤酮给药后 2 周内观察到视力丧失,对视网膜神经节细胞没有明显影响。视网膜神经节细胞的死亡发生在稍后阶段。使用我们的大鼠模型,我们研究了酵母替代 NADH 脱氢酶 Ndi1 的影响。我们通过将 NDI1 基因递送到上丘的光学层,成功地使 Ndi1 蛋白在所有视网膜神经节细胞和轴突的线粒体中得到有效表达。值得注意的是,即使大鼠的视力严重受损,用 NDI1 基因治疗动物也能使视力完全恢复到正常水平。接受空载体或 GFP 基因的对照组没有效果。
结论/意义:本研究报告了大鼠中出现 LHON 样症状的成功表现,并证明了 NDI1 基因治疗对视神经线粒体病变的潜力。我们的结果表明,在疾病症状出现后,成功应用基因治疗的机会之窗。